Sergey Yurasov News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Black Diamond Therapeutics (BDTX) Reports Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535

Black Diamond Therapeutics (BDTX) Reports Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Black diamondUnited statesSergey yurasovPatrick wenOncology at dana farber cancer instituteInternational conference on molecularDiamond therapeutics incIvy brain tumor centerBlack diamond therapeuticsDana farber cancerMolecular targetsResponse assessmentChief medical officer

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Initial results show promising clinical activity in heavily pretreated patients 22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and.

United statesBlack diamondUnited kingdomMario corsoPatrick wenSergey yurasovIvy brain tumor centerDiamond therapeutics incCompany masterkeyExchange commissionInternational conference on molecularOncology at dana farber cancer instituteDiamond therapeuticsDana farber cancerMolecular targetsResponse assessment

Ivy Center Announces First Patient Treated in Targeted

Study tests targeted agent, BDTX-1535, an EGFR inhibitor with brain-penetrant properties.

United statesBlack diamondSergey yurasovNader sanaiIvy brain tumor centerIvy centerNeurosurgical oncology at barrow neurological instituteIvy brain tumor center on facebookIvy center phaseBarrow neurological instituteNeurosurgical oncologyBarrow neurologicalChief medical officerBrain tumor centerBrain tumor researchBrain cancer research

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety or tolerability signal reported across all three.

United statesUnited kingdomMario corsoHelena yuJulie seidelSergey yurasovDiamond therapeutics incInternational conference on molecularMemorial sloan kettering cancer centerExchange commissionCompany masterkeyGlobenewswire incDiamond therapeuticsMolecular targetsCancer therapeuticsGeneration inhibitor

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMario corsoJulie seidelHelena yuSergey yurasovCompany masterkeyInternational conference on molecularPhysician at memorial sloan kettering cancer centerDiamond therapeutics incExchange commissionDiamond therapeuticsMolecular targetsCancer therapeuticsGeneration inhibitorNon small cell lung cancer